By: Stijn Huijts (The Thicket)
The UK Supreme Court issued an interesting judgment yesterday involving the question whether the CMA should cover a party’s litigation costs when that party successfully appeals the CMA’s decision under the Competition Act.
The judgment is related to the CMA’s decision to impose penalties on Pfizer and Flynn Pharma for hiking up the prices of phenytoin sodium capsules, an epilepsy drug. This was a high-profile decision that sought to set a standard for determining when prices charged for drugs that had gone off-patent were excessive and unfair, and therefore in breach of the Chapter II prohibition (i.e., the UK prohibition on the abuse of a dominant position).
The CAT’s costs ruling
The CMA’s decision against Pfizer and Flynn was overturned on appeal by the Competition Appeal Tribunal (CAT) (and parts of the CAT’s judgment were, in turn, successfully appealed by the CMA in the Court of Appeal). The CAT issued a cost order at the end of the appeal, ordering the CMA to pay part of Pfizer and Flynn’s litigation costs.
The basis for the CAT’s order is currently rule 104 of the CAT’s Rules, which holds that the CAT may at its discretion make “any order it thinks fit in relation to the payment of costs”. The Rules add that in doing so, the CAT may take account of a number of factors, including whether a party has succeeded on part of its case and whether costs were proportionately and reasonably incurred and were proportionate and reasonable in amount. There is however no presumption that “the loser pays”…
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI